Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J.P. Morgan Notebook: Wednesday, January 15

This article was originally published in The Pink Sheet Daily

Executive Summary

We bring you news and notes from the third day of the 2014 J.P. Morgan Healthcare conference, which includes highlights from Genentech, Teva, Sarepta, and new accelerator StartUp Health.

You may also be interested in...



After CEO’s Abrupt Resignation, Teva Management Emphasizes Stability

A day after announcing the abrupt resignation of CEO Jeremy Levin, Teva’s management emphasized that the company’s current strategy would continue, including plans for dealing with ongoing pressures from Copaxone’s loss of exclusivity, and under-performance of the European generics businesses. Teva hoped to persuade rattled investors of its steady road to growth.

Health Care Information Technology: Venture's New Darling?

As traditional venture-like returns are harder to generate from drug development and medtech plays, some frustrated VCs see new opportunities in health care information technology, an area many have traditionally avoided.

Imperial Innovations Raises 140 Million To Invest In University Spin-Outs

The AIM-listed tech transfer group Imperial Innovations has raised £140 million to increase its early-stage investments in spin-outs from Imperial College and three other top UK universities

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS076384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel